<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01954914</url>
  </required_header>
  <id_info>
    <org_study_id>TUD-MOBIL1-056</org_study_id>
    <nct_id>NCT01954914</nct_id>
  </id_info>
  <brief_title>Plerixafor as a Salvage Regimen to Mobilize Allogeneic Stem Cells in Healthy Volunteers</brief_title>
  <acronym>MOBIL1</acronym>
  <official_title>Plerixafor as a Salvage Regimen to Mobilize Allogeneic Stem Cells in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Carl Gustav Carus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cellex Gesellschaft für Zellgewinnung mbH Dresden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cellex Gesellschaft für Zellgewinnung mbH Köln</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      With a standard mobilization regimen using G-CSF, approximately 5% of allogeneic donors does&#xD;
      not mobilize enough CD34+ cells to reach an optimal dose for transplantation and are&#xD;
      therefore called &quot;poor mobilizers&quot;. A generally accepted optimum CD34+ PBSC dose for&#xD;
      allogeneic transplantation is &gt; 4.5 x 106/kg body weight of the recipient. The minimum total&#xD;
      CD34+ PBSC dose certainly amounts to 2 x 106/kg body weight of the recipient.The objective of&#xD;
      this trial is to assess the efficacy of a single dose of Plerixafor as salvage procedure in&#xD;
      allogeneic stem cell donors with a poor CD34+ cell yield after the first day of peripheral&#xD;
      blood stem cell collection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this trial the administration of a single dose of Plerixafor 240 µg/kg body weight of the&#xD;
      donor SC in the evening at 10 PM after frustraneous stem cell apheresis on day 1 will be&#xD;
      provided. The apheresis on day 2 is performed according to standard recommendations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of donation success</measure>
    <time_frame>1 day</time_frame>
    <description>A generally accepted optimum CD34+ PBSC dose for allogeneic transplantation is &gt; 4.5 x 10e6/kg body weight of the recipient. The minimum total CD34+ PBSC dose certainly amounts to 2 x 10e6/kg body weight of the recipient.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of donor safety and tolerability based on self-reporting on a questionnaire, clinical findings, and laboratory evaluations; and evaluation of the cellular composition of the apheresis products collected with and without Plerixafor application.</measure>
    <time_frame>30 days</time_frame>
    <description>The composition of apheresis products collected after filgrastim or filgrastim plus Plerixafor will be characterized with respect to:&#xD;
CD34+ cell subsets (differential expression of prominin1/CD133+)33&#xD;
Regulatory T-cells34&#xD;
Dendritic cells&#xD;
Myeloid-derived suppressor cells</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Blood Stem Cell Harvest Failure</condition>
  <arm_group>
    <arm_group_label>Plerixafor, Mozobil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of a single dose of Plerixafor 240 µg/kg body weight of the donor SC in the evening at 10 PM after frustraneous stem cell apheresis on day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plerixafor</intervention_name>
    <description>Administration of a single dose of Plerixafor 240 µg/kg body weight of the donor SC in the evening at 10 PM after frustraneous stem cell apheresis on day 1.</description>
    <arm_group_label>Plerixafor, Mozobil</arm_group_label>
    <other_name>Mozobil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Donor age between 18 years and 75 years&#xD;
&#xD;
          -  Eligibility of the donor for allogeneic PBSC donation according to German Guidelines&#xD;
             (Richtlinien Hämotherapie Bundesärztekammer 2005) preceding the application of G-CSF&#xD;
&#xD;
          -  The donor has understood and signed the donor information. Written informed consent&#xD;
             has been obtained.&#xD;
&#xD;
          -  Donation of less than 2.0 x 106 CD34 cells/kg recipient body weight after one&#xD;
             apheresis following five days of stem-cell mobilization with Lenograstim 7.5 to 10&#xD;
             µg/kg donor body weight&#xD;
&#xD;
          -  First leukapheresis according to standard recommendations with a processing of 3 x&#xD;
             donor's blood volume ± 10% using either of the following three devices: Cobe Spectra&#xD;
             (Terumo BCT) Spectra Optia (Terumo BCT) Fresenius COM.TEC&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pain or any discomfort in the left upper square of the abdomen during physical&#xD;
             examination immediately prior to study inclusion or any spontaneous complaint about&#xD;
             abdominal discomfort without an ultrasound investigation which rules out splenomegaly.&#xD;
&#xD;
          -  Palpitations or any thoracic discomfort in the absence of an ECG which shows normal&#xD;
             results&#xD;
&#xD;
          -  Platelet count &lt; 80 x 109/l&#xD;
&#xD;
          -  Serum creatinine &gt; 80 µmol/l for female donors or &gt; 106 µmol/l for male donors. If&#xD;
             serum creatinine is elevated then the estimated creatinine clearance has to be &gt; 50&#xD;
             ml/min. Estimation by the Modification of Diet in Renal Disease equation where&#xD;
             predicted GFR(ml/min/1.73m2) = 186 x (Serum Creatinine in mg/dL)-1.154 x (age in&#xD;
             years)-0.203 x (0.742 if patient is female) x (1.212 if patient is black) or&#xD;
             GFR(ml/min/1.73m2) = 186 x 176 (Serum Creatinine in µmol/l)-1.154 x (age in&#xD;
             years)-0.203 x (0.742 if patient is female) x (1.212 if patient is black)&#xD;
&#xD;
          -  Contraindications against a second leukapheresis, such as severe side effects during&#xD;
             1st leukapheresis (intolerable pain, severe circulatory disorder, severe citrate&#xD;
             intolerance)&#xD;
&#xD;
          -  Missing written approval by the transplant center that the transplantation of the&#xD;
             Plerixafor-mobilized graft is being considered&#xD;
&#xD;
          -  Treatment with any known non-marketed drug substance or experimental therapy within 4&#xD;
             weeks prior to enrolment or participation in any other interventional clinical study&#xD;
&#xD;
          -  Any significant concurrent disease, illness, or psychiatric disorder that would&#xD;
             compromise donor safety or compliance, interfere with consent, study participation,&#xD;
             follow up, or interpretation of study results&#xD;
&#xD;
          -  Female donors of childbearing potential unable or unwilling to use adequate&#xD;
             contraception methods for three months after the administration of the study drug.&#xD;
             Adequate methods for contraception in female donors are sexual abstinence, the use of&#xD;
             condoms by their partners, vasectomy of the partner or hormonal contraception.&#xD;
&#xD;
          -  Male donors unable or unwilling to use adequate contraception methods for one month&#xD;
             after the administration of the study drug. Adequate methods for contraception for&#xD;
             males are sexual abstinence or the use of condoms.&#xD;
&#xD;
          -  Known intolerance to Plerixafor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristina Hölig, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Carl Gustav Carus, Medizinische Klinik und Poliklinik I, 01307 Dresden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cellex Gesellschaft für Zellgewinnung mbH Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Dresden, Medizinische Klinik I</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cellex Gesellschaft für Zellgewinnung mbH Köln</name>
      <address>
        <city>Köln</city>
        <zip>50670</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>September 27, 2013</study_first_submitted>
  <study_first_submitted_qc>September 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2013</study_first_posted>
  <last_update_submitted>September 16, 2016</last_update_submitted>
  <last_update_submitted_qc>September 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Plerixafor</keyword>
  <keyword>donor</keyword>
  <keyword>allogeneic peripheral stam cell donation</keyword>
  <keyword>PBSC</keyword>
  <keyword>poor donors</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plerixafor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

